Adherence To Current Guidelines For Chronic Obstructive Pulmonary Disease (COPD) In Subjects Treated With Combination Of Long-Acting Beta2-Agonist (LABA), Long-Acting Muscarinic Antagonist (LAMA) Or Inhaled Corticosteroids (ics)

被引：0
|
作者：
Asche, C. V.
Leader, S.
Plauschinat, C.
Raparla, S.
Yan, M.
Ye, X.
Young, D.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3115
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
    Skolnik, Neil S.
    Nguyen, Trang Susan
    Shrestha, Aarisha
    Ray, Riju
    Corbridge, Thomas C.
    Brunton, Stephen A.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 198 - 205
  • [42] Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS
    Latorre, M.
    Novelli, F.
    Vagaggini, B.
    Braido, F.
    Papi, A.
    Sanduzzi, A.
    Santus, P.
    Scichilone, N.
    Paggiaro, P.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 30 : 44 - 50
  • [43] The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
    Zhou, Ji'an
    Zhang, Jing
    Zhou, Min
    Hang, Jingqing
    Zhang, Min
    Han, Fengfeng
    Zhu, Huili
    JOURNAL OF THORACIC DISEASE, 2021, 13 (11) : 6453 - 6467
  • [44] Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease
    Yongqian Xu
    Yu Pang
    Pharmaceutical Chemistry Journal, 2023, 57 : 365 - 372
  • [45] Management of Chronic Obstructive Pulmonary Disease: Insights into Patient Profile - Use of Inhaled Corticosteroids/Long-Acting β2-Agonists or Long-Acting β2-Agonists/Long-acting Muscarinic Antagonists
    Kishore, Nevin
    Moitra, Saibal
    Sircar, Mrinal
    INDIAN JOURNAL OF RESPIRATORY CARE, 2020, 9 (02) : 162 - 170
  • [46] CLINICAL EFFICACY OF LONG-ACTING β2 AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONIST FOR MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Xu, Yongqian
    Pang, Yu
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2023, 57 (3) : 365 - 372
  • [47] Combination long-acting β2-agonists and inhaled corticosteroids in chronic obstructive pulmonary disease -: In response
    Vestbo, J
    CLINICAL MEDICINE, 2004, 4 (05) : 470 - 470
  • [48] Adherence to Long-Acting Inhaled Therapies among Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Cecere, Laura M.
    Slatore, Christopher G.
    Uman, Jane E.
    Evans, Laura E.
    Udris, Edmunds M.
    Bryson, Chris L.
    Au, David H.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 9 (03) : 251 - 258
  • [49] Once-daily long-acting beta 2-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease
    Sliwka, Agnieszka
    Jankowski, Milosz
    Gross-Sondej, Iwona
    Storman, Monika
    Nowobilski, Roman
    Bala, Malgorzata M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (08):
  • [50] Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease
    Spencer, Sally
    Evans, David J.
    Karner, Charlotta
    Cates, Christopher J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10):
12345